On June 6, 2023 CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, reported a partnership with xCures, Inc., to connect cancer patients and physicians with optimal investigational or approved therapies (Press release, xCures, JUN 6, 2023, View Source [SID1234632525]). CureMatch will leverage the xCures technology platform to create a comprehensive outline of a cancer patient’s medical history and further enhance its precision cancer treatment recommendation capabilities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CureMatch analyzes an individual patient’s genetic sequencing report to determine which drug combinations, out of the millions possible, could most effectively treat their cancer. It then provides oncologists with clear, accessible, predictive treatment analysis in an easy-to-read report that equips them with actionable knowledge tailored for each unique case. With xCures, cancer patients get immediate access to their care summary and all of their medical data in one easy-to-access place, greatly facilitating the finding of promising treatment options, even as they seek second opinions and try new therapies.
The collaboration between CureMatch and xCures will give oncologists clear, comprehensive access to patient records and past treatments, enabling them to make more informed recommendations for combination precision cancer treatments based on the CureMatch report.
"The collaboration between xCures and CureMatch brings together two leading companies at the forefront of digital healthcare innovation," said Mika Newton, CEO of xCures. "By combining our strengths, we are confident that we can accelerate the adoption of precision oncology and improve outcomes for cancer patients globally."
"This partnership represents a significant step forward in harnessing the power of AI technology to optimize cancer care," said Navid Alipour, CEO of CureMatch. "By combining xCures’ patient medical history platform and our treatment-matching algorithm, we can make the process of obtaining genetically tailored, precision cancer therapies a reality for more patients."